Relationship Between Pain Alleviation and Disease-specific Health-related Quality of Life Measures in Patients With Chronic Low Back Pain Receiving Duloxetine: Exploratory Post Hoc Analysis of a Japanese Phase 3 Randomized Study

Hiroyuki Enomoto, Nao Sasaki, Shinji Fujikoshi, Aki Yoshikawa, Toshinaga Tsuji, Katsushi Takeshita, Hiroyuki Enomoto, Nao Sasaki, Shinji Fujikoshi, Aki Yoshikawa, Toshinaga Tsuji, Katsushi Takeshita

Abstract

This post hoc analysis of a Japanese phase 3 randomized study (ClinicalTrials.gov identifier: NCT01855919) investigated relationships between pain severity (assessed by the Brief Pain Inventory [BPI]) and disease-specific health-related quality of life (assessed by the 24-item Roland-Morris Disability Questionnaire [RDQ-24]) in duloxetine-treated patients with chronic low back pain (CLBP).

Methods: Patients with CLBP duration >6 months and BPI average score ≥4 received duloxetine 60 mg/d (N = 230) or placebo (N = 226) for 14 weeks. Spearman rank correlation coefficients were calculated for (1) BPI change from baseline and RDQ item change from baseline and (2) BPI change from baseline and the RDQ item baseline score in duloxetine-treated patients.

Results: Duloxetine treatment significantly improved the RDQ-24 total score compared with placebo; the greatest improvements were observed for RDQ02, RDQ17, and RDQ13. The strongest correlations between BPI change from baseline and RDQ item change from baseline were for RDQ13, RDQ23, and RDQ10. The correlation coefficients for the correlations between BPI change from baseline and the RDQ item baseline score were generally small.

Discussion: This post hoc analysis suggested that improvement in pain severity was associated with improvement in the RDQ-24 total score and in some individual RDQ items in duloxetine-treated patients with CLBP. Furthermore, positive responses to duloxetine in terms of the RDQ13, RDQ23, and RDQ10 items may correlate with better pain responses.

Clinical trial registry: The study described in this manuscript was registered at www.clinicaltrials.gov (NCT01855919).

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons.

References

    1. Japanese Orthopedic Association (JOA): Clinical Practice Guideline for the Management of Low Back Pain (in Japanese). Tokyo, Nankodo Co., Ltd., 2012.
    1. Bogduk N: Management of chronic low back pain. Med J Aust 2004;180:79-83.
    1. Mokdad AH, Forouzanfar MH, Daoud F, et al. : Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2016;387:2383-2401.
    1. Dagenais S, Caro J, Haldeman S: A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008;8:8-20.
    1. Tsuji T, Matsudaira K, Sato H, Vietri J: The impact of depression among chronic low back pain patients in Japan. BMC Musculoskelet Disord 2016;17:447.
    1. Tsuji T, Matsudaira K, Sato H, Vietri J, Jaffe DH: Association between presenteeism and health-related quality of life among Japanese adults with chronic lower back pain: A retrospective observational study. BMJ Open 2018;8:e021160.
    1. Suka M, Yoshida K: Low back pain deprives the Japanese adult population of their quality of life: A questionnaire survey at five healthcare facilities in Japan. Environ Health Prev Med 2008;13:109-115.
    1. Deyo RA, Weinstein JN: Low back pain. N Engl J Med 2001;344:363-370.
    1. Alev L, Fujikoshi S, Yoshikawa A, et al. : Duloxetine 60 mg for chronic low back pain: Post hoc responder analysis of double-blind, placebo-controlled trials. J Pain Res 2017;10:1723-31.
    1. Airaksinen O, Brox JI, Cedraschi C, et al. : Chapter 4: European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;15(suppl 2):S192-S300.
    1. Phillips K, Clauw DJ: Central pain mechanisms in chronic pain states: Maybe it is all in their head. Best Pract Res Clin Rheumatol 2011;25:141-154.
    1. Chou R, Huffman LH; American Pain Society, American College of Physicians: Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:505-514.
    1. Shanthanna H, Gilron I, Rajarathinam M, et al. : Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLoS Med 2017;14:e1002369.
    1. Baron R, Freynhagen R, Tölle TR, et al. : The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-427.
    1. Atkinson JH, Slater MA, Capparelli EV, et al. : A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain 2016;157:1499-1507.
    1. Skljarevski V, Ossanna M, Liu-Seifert H, et al. : A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-1048.
    1. Skljarevski V, Desaiah D, Liu-Seifert H, et al. : Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976) 2010;35:E578-E585.
    1. Skljarevski V, Zhang S, Desaiah D, et al. : Duloxetine versus placebo in patients with chronic low back pain: A 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-1290.
    1. Konno S, Oda N, Ochiai T, Alev L: Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back pain. Spine (Phila Pa 1976) 2016;41:1709-1717.
    1. Smith HS, Smith EJ, Smith BR: Duloxetine in the management of chronic musculoskeletal pain. Ther Clin Risk Manag 2012;8:267-277.
    1. Wang CF, Russell G, Strichartz GR, Wang GK: The local and systemic actions of duloxetine in allodynia and hyperalgesia using a rat skin incision pain model. Anesth Analg 2015;121:532-544.
    1. Yamashita T, Yamamoto S, Zhang J, et al. : Duloxetine inhibits microglial P2X4 receptor function and alleviates neuropathic pain after peripheral nerve injury. PLoS One 2016;11:e0165189.
    1. Skljarevski V, Zhang S, Iyengar S, et al. : Efficacy of duloxetine in patients with chronic pain conditions. Curr Drug Ther 2011;6:296-303.
    1. Deyo RA, Dworkin SF, Amtmann D, et al. : Report of the NIH Task Force on research standards for chronic low back pain. J Pain 2014;15:569-585.
    1. Roland M, Morris R: A study of the natural history of back pain. Part I: Development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976) 1983;8:141-144.
    1. Fukuhara S, ed: RDQ (Roland-Morris Disability Questionnaire) Japanese Manual (in Japanese). Tokyo, Iryobunkasha, 2004.
    1. Suzukamo Y, Fukuhara S, Kikuchi S, et al. : Validation of the Japanese version of the Roland-Morris Disability Questionnaire. J Orthop Sci 2003;8:543-548.
    1. Tsuji T, Itoh N, Ishida M, Ochiai T, Konno S: Response to duloxetine in chronic low back pain: Exploratory post hoc analysis of a Japanese phase III randomized study. J Pain Res 2017;10:2157-2168.
    1. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F: A brief cancer pain assessment tool in Japanese: The utility of the Japanese Brief Pain Inventory—BPI-J. J Pain Symptom Manage 1998;16:364-373.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, et al. : The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
    1. Posner K, Brown GK, Stanley B, et al. : The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.
    1. Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM, Disability Risk Identification Study Cohort: Early opioid prescription and subsequent disability among workers with back injuries: The Disability Risk Identification Study Cohort. Spine (Phila Pa 1976) 2008;33:199-204.
    1. Krebs EE, Gravely A, Nugent S, et al. : Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA 2018;319:872-882.
    1. Knezevic NN, Mandalia S, Raasch J, Knezevic I, Candido KD: Treatment of chronic low back pain - new approaches on the horizon. J Pain Res 2017;10:1111-1123.
    1. Ogawa K, Fujikoshi S, Montgomery W, Alev L: Correlation between pain response and improvements in patient-reported outcomes and health-related quality of life in duloxetine-treated patients with diabetic peripheral neuropathic pain. Neuropsychiatr Dis Treat 2015;11:2101-2107.
    1. Bouhassira D, Wilhelm S, Schacht A, et al. : Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain 2014;155:2171-2179.
    1. Tesfaye S, Wilhelm S, Lledo A, et al. : Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study”—a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013;154:2616-2625.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner